The Business Research Company's report on the Unresectable Hepatocellular Carcinoma Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the unresectable hepatocellular carcinoma market further?
The increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market going forward. Liver cancer refers to the healthy, functioning cells of the liver being taken over by tumor cells as they start to develop uncontrollably. Unresectable hepatocellular carcinoma is a type of cancer treated by liver transplantation and radiofrequency ablation. For instance, in October 2022, according to the Journal of Hepatology, a Switzerland-based peer-reviewed scientific journal, globally, 830,200 people lost their lives to liver cancer by the year 2020. and there will probably be 1.4 million new cases of liver cancer diagnosed between 2020 and 2040, an increase of 55.0% in the number of new cases per year. Furthermore, in January 2024, according to the American Cancer Society, a US-based non-profit organization, an estimated 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer are expected to be diagnosed in the U.S. in 2024 (28,000 in men and 13,630 in women), with about 29,840 deaths projected (19,120 men and 10,720 women). Therefore, the increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market.
Access Your Free Sample of the Global Unresectable Hepatocellular Carcinoma Market Report – Get Insights Now!
Unresectable Hepatocellular Carcinoma Market Report 2025, Trends 2034 Sample
What are the key factors influencing the forecasted market size of the unresectable hepatocellular carcinoma industry?
The unresectable hepatocellular carcinoma market size has grown marginally in recent years. It will grow from $1.98 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to chemotherapy advances, clinical trial outcomes, liver transplantation limitations, increased cancer cases, expanded access to therapies
The unresectable hepatocellular carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.95 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to healthcare policy changes, patient stratification strategies, real-world evidence utilization, patient advocacy and awareness, economic and dynamics. Major trends in the forecast period include precision medicine and biomarkers, real-world evidence and data integration, multidisciplinary approaches, global clinical trials and collaborations, and patient-centric care.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
Unresectable Hepatocellular Carcinoma Market Report 2025, Trends 2034 Customise
Who are the leading competitors in the unresectable hepatocellular carcinoma market?
Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.
Which emerging trends are set to transform the unresectable hepatocellular carcinoma market landscape?
Product innovations are a key trend gaining popularity in the unresectable hepatocellular carcinoma market. Major companies operating in the unresectable hepatocellular carcinoma market are adopting innovative products to sustain their position in the market. For instance, in October 2022, AstraZeneca, a UK-based pharmaceutical and biotechnology company, launched FDA-approved Imjudo (tremelimumab) in combination with Imfinzi in the US for patients with unresectable liver cancer. The new treatment, known as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), consists of a single dosage of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500 mg every four weeks. Patients who received Imjudo and Imfinzi together had a 22% lower chance of passing away than those who received sorafenib.
How do different geographies compare in terms of market share and growth potential in the unresectable hepatocellular carcinoma market?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
Unresectable Hepatocellular Carcinoma Market Report 2025, Trends 2034
Which major segments of the unresectable hepatocellular carcinoma market are experiencing the fastest growth?
The unresectable hepatocellular carcinoma market covered in this report is segmented –
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer, Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma, Focal Nodular Hyperplasia, Hemangiomas
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
Unresectable Hepatocellular Carcinoma Market Report 2025, Trends 2034
How is the unresectable hepatocellular carcinoma market defined, and what are its core characteristics?
Unresectable hepatocellular carcinoma refers to an aggressive tumor that typically develops alongside cirrhosis and chronic liver disease. The treatment for unresectable hepatocellular carcinoma is surgical resection, liver transplant, ablation, and embolization.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Market Research Reports
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment